CBD-Rich Extract in Autism: Interview Findings and Standardized Scales Diverged
A randomized autism trial reported improvements on selected interview-based outcomes without significant differences on the standardized ATEC and CARS measures. Both findings belong in any account of the study.
A specific 12-week experiment
Sixty children aged five to eleven received a CBD-rich cannabis extract or placebo under double-blind conditions for 12 weeks. The researchers used interviews as well as the Autism Treatment Evaluation Checklist and Childhood Autism Rating Scale.
The intervention was an extract, not isolated CBD. Its results apply to the tested preparation and population rather than every product labeled cannabis or CBD.
The endpoint determines the conclusion
Reported significant findings included social interaction, anxiety, psychomotor agitation and meals per day. The concentration finding was limited to the mild-ASD subgroup.
The paper did not find significant differences on the ATEC measures or CARS. It would therefore be inaccurate to describe every standardized measure of autism features as improved. Conversely, those null scale comparisons do not erase the separately reported interview findings.
Interpretation requires the entire pattern
Multiple endpoints and subgroup analyses increase the importance of distinguishing the primary question from exploratory comparisons. Different instruments may capture different constructs and may have different sensitivities.
The trial also overlapped the coronavirus pandemic, with participants beginning treatment under different routine conditions. The authors identified this as a limitation. The 12-week period cannot establish long-term developmental safety or durable benefit.
The appropriate conclusion is a qualified, preparation-specific signal on selected outcomes. It does not establish a cure for autism, uniform improvement in core features or a reliable prediction of response for an individual child.
Related analysis
See our analysis of why developmental cannabinoid findings require precise endpoints.
Primary research
Estácio Amaro da Silva Junior and colleagues. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. Trends in Psychiatry and Psychotherapy. DOI: 10.47626/2237-6089-2021-0396.
